Pfizer wins China approval for obesity drug , escalating competition in high-growth market. China's regulatory clearance for Pfizer's GLP-1 weight management drug marks a significant expansion into one of the world's largest pharmaceutical markets. The approval comes as the obesity treatment sector experiences explosive growth globally, with multiple competitors racing to capture market share. However, Pfizer faces mounting pressure from generic alternatives expected to enter the market soon, which could compress pricing and margins. The competitive landscape is intensifying as other pharmaceutical companies develop similar GLP-1 medications. China's approval represents a major revenue opportunity for Pfizer, but the company must act quickly to establish market dominance before generics erode profitability.